IHT Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $347K | Sell |
557
-30
| -5% | -$20.4K | 0.01% | 971 |
|
|
2026
Q1 | $453K | Sell |
587
-6
| -1% | -$4.59K | 0.01% | 860 |
|
|
2025
Q4 | $457K | Sell |
593
-21
| -3% | -$14.3K | 0.01% | 805 |
|
|
2025
Q3 | $345K | Sell |
614
-29
| -5% | -$16.4K | 0.01% | 871 |
|
|
2025
Q2 | $338K | Buy |
643
+23
| +4% | +$12.8K | 0.01% | 832 |
|
|
2025
Q1 | $393K | Sell |
620
-62
| -9% | -$42.6K | 0.01% | 751 |
|
|
2024
Q4 | $486K | Sell |
682
-19
| -3% | -$15.9K | 0.02% | 690 |
|
|
2024
Q3 | $736K | Buy |
701
+103
| +17% | +$115K | 0.02% | 590 |
|
|
2024
Q2 | $629K | Sell |
598
-1
| -0.2% | -$969 | 0.02% | 567 |
|
|
2024
Q1 | $577K | Sell |
599
-16
| -3% | -$15.2K | 0.02% | 584 |
|
|
2023
Q4 | $540K | Buy |
615
+40
| +7% | +$32.9K | 0.02% | 573 |
|
|
2023
Q3 | $473K | Buy |
575
+14
| +2% | +$11K | 0.02% | 571 |
|
|
2023
Q2 | $403K | Buy |
561
+17
| +3% | +$13.1K | 0.02% | 615 |
|
|
2023
Q1 | $447K | Buy |
544
+17
| +3% | +$12.8K | 0.03% | 542 |
|
|
2022
Q4 | $380K | Sell |
527
-123
| -19% | -$90.8K | 0.02% | 570 |
|
|
2022
Q3 | $448K | Buy |
650
+267
| +70% | +$168K | 0.03% | 486 |
|
|
2022
Q2 | $226K | Sell |
383
-30
| -7% | -$19.5K | 0.02% | 628 |
|
|
2022
Q1 | $288K | Buy |
413
+21
| +5% | +$13.3K | 0.02% | 582 |
|
|
2021
Q4 | $248K | Buy |
392
+19
| +5% | +$11.7K | 0.02% | 679 |
|
|
2021
Q3 | $226K | Sell |
373
-242
| -39% | -$150K | 0.02% | 699 |
|
|
2021
Q2 | $344K | Buy |
615
+5
| +0.8% | +$2.53K | 0.02% | 652 |
|
|
2021
Q1 | $289K | Sell |
610
-23
| -4% | -$11.2K | 0.02% | 644 |
|
|
2020
Q4 | $306K | Buy |
633
+38
| +6% | +$20.5K | 0.03% | 556 |
|
|
2020
Q3 | $333K | Sell |
595
-1,030
| -63% | -$625K | 0.03% | 450 |
|
|
2020
Q2 | $1.01M | Buy |
1,625
+1,119
| +221% | +$635K | 0.14% | 161 |
|
|
2020
Q1 | $247K | Buy |
+506
| New | +$209K | 0.04% | 444 |
|
|
2019
Q1 | – | Sell |
-1,300
| Closed | -$486K | – | 541 |
|
|
2018
Q4 | $486K | Sell |
1,300
-127
| -9% | -$46.5K | 0.09% | 253 |
|
|
2018
Q3 | $577K | Sell |
1,427
-280
| -16% | -$107K | 0.12% | 204 |
|
|
2018
Q2 | $589K | Buy |
1,707
+173
| +11% | +$54.1K | 0.15% | 180 |
|
|
2018
Q1 | $507K | Buy |
1,534
+73
| +5% | +$25.4K | 0.14% | 182 |
|
|
2017
Q4 | $544K | Buy |
1,461
+1,418
| +3,298% | +$574K | 0.14% | 176 |
|
|
2017
Q3 | $20K | Sell |
43
-46
| -52% | -$21.9K | 0.01% | 781 |
|
|
2017
Q2 | $14K | Sell |
89
-21
| -19% | -$9.19K | 0.01% | 872 |
|
|
2017
Q1 | $42K | Buy |
110
+4
| +4% | +$1.48K | 0.03% | 459 |
|
|
2016
Q4 | $40K | Buy |
+106
| New | +$40.3K | 0.03% | 433 |
|
Other funds holding REGN
IHT Wealth Management's REGN Position: Q2 2026 in Review
IHT Wealth Management reduced its Regeneron Pharmaceuticals (REGN) stake by 5.1% in Q2 2026, selling an estimated $20.4K and leaving 557 shares worth $347K. The position accounts for 0.01% of the portfolio, ranked #971.
IHT Wealth Management first reported a position in REGN in Q4 2016 and has held it in 35 quarters since. The position peaked at $1.01M in Q2 2020. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- IHT Wealth Management held 557 shares of Regeneron Pharmaceuticals worth $347K as of Q2 2026.
- IHT Wealth Management sold 30 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $20.4K.
- Regeneron Pharmaceuticals made up 0.01% of IHT Wealth Management's portfolio in Q2 2026, its #971 holding.
- IHT Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 35 quarters since.
- IHT Wealth Management's Regeneron Pharmaceuticals position peaked at $1.01M in Q2 2020.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on IHT Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.